SCHEMBL5853141

SCHEMBL5853141

COC(=O)c1cc(C(F)(F)F)cc(N2CCCC2=O)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.41
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40
BACE1 P56817 1/20 0.40
NOTUM Q6P988 2/20 0.39
MOGAT2 Q3SYC2 4/20 0.39
LRRK2 Q5S007 2/20 0.38
MGAT2 Q10469 1/20 0.37
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SOS1 Q07889 1/20 0.36
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
BDKRB1 P46663 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5219744 0.86 ALDH1A1 (0.42) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL5851474 0.84 SMN1; SMN2 (0.42) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL5219064 0.84 HSD17B10 (0.42) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL5216170 0.83 HSD17B10 (0.41) CYP3A4CYP2C9NOTUMHSD17B10LMNA
SCHEMBL5222867 0.80 HSD17B10 (0.36) CYP3A4CYP2C9HSD17B10LMNAHPGD
SCHEMBL5855036 0.80 GABRP (0.44) CFTRNOTUMMOGAT2KDM4ELMNA
SCHEMBL5222872 0.80 HSD17B10 (0.36) CYP3A4CYP2C9HSD17B10LMNAHPGD
SCHEMBL5222877 0.80 HSD17B10 (0.36) CYP3A4CYP2C9HSD17B10LMNAHPGD
SCHEMBL5221159 0.79 LMNA (0.39) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19
SCHEMBL5216498 0.79 BACE1 (0.47) CYP3A4CYP2C9CYP1A2CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992103-B2 Benzamide derivatives, processes for their preparation, and their pharmaceutical use SMITHKLINE BEECHAM P.L.C. (GB) 2006-01-31 US disclosed
US-20050085520-A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use SMITHKLINE BEECHAM P.L.C. (GB) 2005-04-21 US disclosed
EP-1448520-A1 BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM PLC (GB) 2004-08-25 EP disclosed
WO-2003045913-A1 BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085520-A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use BACE2, PSEN2, BACE1 CFTR 2316/4885CYP3A4 1731/4885CYP2C9 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.